Maintained improvement of outcomes related to skin clearance, itch, sleep and quality of life with baricitinib in adults with moderate-to-severe Atopic Dermatitis who were treated for up to 200 weeks in a randomized trial
Por:
Wollenberg, A, Costanzo, A, Vestergaard, C, Masuda, K, Morawska, K, Vardar, B, Pandey, H, Sabatino, S and Carrascosa, JM
Publicada:
31 dic 2025
Ahead of Print:
27 nov 2025
Resumen:
ObjectiveTo report response maintenance in patients with moderate-to-severe Atopic Dermatitis (AD) upon continuous or downtitrated baricitinib treatment for 200 weeks.MethodsPatients with vIGA-AD (R) (validated Investigator Global Assessment for Atopic Dermatitis) score <= 2 at Week 52 treated with baricitinib 4 mg were re-randomized (1:1:1) to continue (4 mg), down-titrate (2 mg) or dose withdrawal (placebo). Response to continuous and downtitrated treatment was assessed from Week 52 to 200 in the overall substudy population (vIGA-AD 0,1,2) and in substudy patients with higher response (vIGA-AD 0,1) at Week 52.ResultsEfficacy was maintained in Week 52 responders (vIGA-AD 0,1,2) continuing baricitinib 4 mg, as measured by vIGA-AD (0,1) (Week 52 [51.2%], Week 200 [51.2%]); Eczema Area and Severity Index (EASI) 75 (Week 52 [82.1%], Week 200 [79.8%]). Patients with vIGA-AD (0,1) at Week 52 maintained higher response rates during continued treatment and after down-titration compared with overall substudy population.ConclusionAD symptom improvement was maintained up to Week 200 with baricitinib 4 mg. After down-titration, the vIGA-AD (0,1) response patient subgroup maintained clear or almost clear skin and itch response improvement. Clear or almost clear skin achievement may help identify optimal candidates for down-titration after 52 weeks of full-dose treatment.
Filiaciones:
Wollenberg, A:
Univ Hosp Augsburg, Dept Dermatol & Allergy, Sauerbruchstr 6, D-86179 Augsburg, Germany
Univ Lubeck, Comprehens Ctr Inflammat Med, Lubeck, Germany
Ludwig Maximilians Univ Munchen, Dept Dermatol & Allergy, Munich, Germany
Costanzo, A:
Univ Med Sch Dermatol, Via Alessandro Manzoni, Rozzano, Italy
Vestergaard, C:
Aarhus Univ Hosp, Aarhus, Denmark
Masuda, K:
Kyoto Prefectural Univ Med, Dept Dermatol, Kyoto, Japan
Morawska, K:
Eli Lilly & Co, Indianapolis, IN USA
Vardar, B:
Eli Lilly & Co, Indianapolis, IN USA
Pandey, H:
Eli Lilly & Co, Indianapolis, IN USA
Sabatino, S:
Eli Lilly & Co, Indianapolis, IN USA
:
Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, IGTP, Badalona, Spain
Green Submitted, gold
|